Rupert D'Souza - 13 May 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Chief Financial Officer
Signature
Rupert D'Souza, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
13 May 2022
Net transactions value
+$16,857
Form type
4
Filing time
17 May 2022, 18:28:44 UTC
Previous filing
08 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Purchase $8,585 +10,000 +1176% $0.8585 10,850 13 May 2022 Direct F1
transaction ADVM Common Stock Purchase $8,272 +10,000 +92% $0.8272 20,850 17 May 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.856 to $0.865. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F2 Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.8245 to $0.828. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.